Entera Bio Ltd
ENTX1.040USD
-0.130-11.11%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
47.49MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Entera Bio Ltd Unternehmen
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Entera Bio Ltd Informationen
BörsenkürzelENTX
Name des UnternehmensEntera Bio Ltd
IPO-datumJun 28, 2018
CEOToledano (Miranda Jayne)
Anzahl der mitarbeiter18
WertpapierartOrdinary Share
GeschäftsjahresendeJun 28
AddresseHadassah / Jerusalem Bio
StadtJERUSALEM
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl9112002
Telefon97225327151
Websitehttps://enterabio.com/
BörsenkürzelENTX
IPO-datumJun 28, 2018
CEOToledano (Miranda Jayne)
Führungskräfte von Entera Bio Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
363.25K
+38294.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
302.45K
+11000.00%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
160.10K
+25371.00%
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
90.98K
+26329.00%
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
77.42K
+30157.00%
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
75.66K
+28721.00%
Dr. Hillel Galitzer
Dr. Hillel Galitzer
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Director
Director
--
--
Dr. Arthur C. Santora
Dr. Arthur C. Santora
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Dana Yaacov-Garbeli
Ms. Dana Yaacov-Garbeli
Chief Financial Officer
Chief Financial Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
363.25K
+38294.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
302.45K
+11000.00%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
160.10K
+25371.00%
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
90.98K
+26329.00%
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
77.42K
+30157.00%
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
75.66K
+28721.00%
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
Andere
62.81%
Aktionäre
Aktionäre
Anteil
Knoll Capital Management, LLC
12.83%
OPKO Health Inc
8.43%
D.N.A Biomedical Solutions, Ltd.
8.14%
Centillion Fund Inc
5.23%
Point72 Asset Management, L.P.
2.57%
Andere
62.81%
Aktionärstypen
Aktionäre
Anteil
Corporation
21.80%
Hedge Fund
17.54%
Individual Investor
2.76%
Investment Advisor/Hedge Fund
1.41%
Investment Advisor
0.69%
Research Firm
0.11%
Venture Capital
0.02%
Andere
55.67%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
31
10.02M
22.66%
--
2025Q3
32
10.02M
22.66%
-49.40K
2025Q2
33
10.07M
22.72%
-152.10K
2025Q1
34
10.22M
23.69%
-537.14K
2024Q4
32
7.49M
20.14%
+518.60K
2024Q3
30
5.32M
15.79%
+29.98K
2024Q2
29
5.29M
11.96%
+1.38M
2024Q1
26
4.27M
12.41%
-130.45K
2023Q4
26
4.07M
8.01%
+1.48M
2023Q3
27
2.59M
10.16%
+9.25K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Knoll Capital Management, LLC
5.88M
12.83%
--
--
Sep 30, 2025
OPKO Health Inc
3.87M
8.43%
+180.00K
+4.88%
May 08, 2025
D.N.A Biomedical Solutions, Ltd.
3.73M
8.14%
--
--
May 08, 2025
Centillion Fund Inc
2.40M
5.23%
--
--
May 08, 2025
Point72 Asset Management, L.P.
1.18M
2.57%
-1.52M
-56.31%
Sep 30, 2025
Marshall Wace LLP
627.33K
1.37%
+627.33K
--
Sep 30, 2025
Schonfeld Strategic Advisors LLC
566.96K
1.24%
-37.57K
-6.21%
Sep 30, 2025
Lieberman (Gerald M)
324.96K
0.71%
--
--
May 08, 2025
Toledano (Miranda Jayne)
302.45K
0.66%
+11.00K
+3.77%
Dec 29, 2025
Parkman Healthcare Partners LLC
280.82K
0.61%
-75.00K
-21.08%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
